All the Drug Class Drugs
Estrogen Receptor Antagonist. Fulvestrant 250 mg / 5 ml. PREFILL. SYRINGE: 2. Adult females,
incl. elderly: 500 mg (2 consec. injects.)
monthly, admin. slow I.M. one in ea.
buttock. Addition. 500 mg dose 2 wks.
aft. init. dose. Child and adolesc: Not
recommend. as safety and efficacy not
established. Mild-mod. ren. impair: No
dose adjust. recommend. Safety and
efficacy not evaluated in severe ren.
impair. Mild-mod. hep. impair: Use
with caution. Safety and efficacy not
evaluated in hep. impair.
Tmt. postmenopaus. women with
estrogen receptor positive, locally
advanced or metastat. breast cancer for dis. relapse on or aft. adjuv. antiestrogen
ther.; or for dis. progress. on ther. with an
antiestrogen.
C/I: Known hypersens., pregn. lact.
Severe hep. impair.
Estrogen Receptor Antagonist. Fulvestrant 250 mg. Pre-filled sir. with sol. for IM inj. 2 X 250 mg/5ml
Adult females: 2 inj. admin. consecutively, one in each buttock. Repeat after 2 weeks.
Tmt. of oestrogen receptor positive, locally advanced or metastat. breast cancer in postmenopausal women: * not previously treated with endocr. ther., or * with dis. relapse on or after adjuvant endocr. ther.; or * with dis. progress. on endocr. ther.
Combin. ther. for the tmt. of: - HR-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in men and postmenopausal women in combin. with ribociclib as initial endocr. based ther. or following dis. progress. on endocr. ther. - HR- positive, human epidermal growth factor receptor 2 (HER2)-neg. advanced or metastatic breast cancer in combin. with palbociclib or abemaciclib in women with dis. progress. after endocr. ther.
C/I:Hypersens. Pregn. and lactat. Sev. hepatic impairm.
Estrogen Receptor Antagonist. Elacestrant 86 mg, 345 mg. FC tab 86/345 mg
345 mg once dly until dis. progress. or unaccept. tox.
tmt. of postmenopausal women or adlt. men with estrogen recept. (ER)-pos., human epidermal growth fact. recept. 2 (HER)-neg., ESR1-mutated adv. or metast. breast cancer with dis. progr. follow. at least 1 line of endocr. ther.
C/I: Hypersens.
